(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Tenaya Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TNYA's revenue for 2024 to be $392,580,710, with the lowest TNYA revenue forecast at $392,580,710, and the highest TNYA revenue forecast at $392,580,710. On average, 2 Wall Street analysts forecast TNYA's revenue for 2025 to be $902,935,633, with the lowest TNYA revenue forecast at $628,129,136, and the highest TNYA revenue forecast at $1,177,742,130.
In 2026, TNYA is forecast to generate $3,684,134,415 in revenue, with the lowest revenue forecast at $1,570,322,840 and the highest revenue forecast at $5,797,945,990.